Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis

Table 1

Data for body weight, liver weight, and biochemical parameters in the normal control (NC), high-fat diet (HFD), pioglitazone control (PC), and high-fat diet plus pioglitazone (HP) groups.

	NC group	HFD group	PC group	HP group
Final body weight (g)	449.7±44.7	643.6±127.5^∗∗∗	426.2±34.9	584.9±65.3
Liver weight (g)	14.4±1.4	32.6±8.2^∗∗∗	11.6±1.5	22.5±3.2^††
Liver/body weight ratio (%)	3.2±0.3	5.0±0.4^∗∗∗	2.7±0.3	3.9±0.6^†††
FPG (mmol/L)	5.5±0.6	11.8±2.6^∗∗∗	7.3±1.2^∗∗	9.8±1.1^†
FINS (mIU/L)	9.5±1.4	21.6±5.5^∗∗∗	8.0±0.8	14.3±1.9^†††
HOMA-IR	2.4±0.6	11.3±3.5^∗∗∗	2.6±0.4	6.3±1.2^†††
TC (mmol/L)	1.9±0.5	3.1±0.5^∗∗∗	1.9±0.2	2.2±0.2^†††
HDL-C (mmol/L)	1.3±0.2	1.6±0.2^∗∗∗	1.3±0.2	1.2±0.1^†††
LDL-C (mmol/L)	0.4±0.1	1.5±0.3^∗∗∗	0.5±0.1	1.0±0.2^†††
TG (mmol/L)	1.1±0.2	2.3±0.3^∗∗∗	0.9±0.2^∗∗	1.0±0.2^†††
FFA (mmol/L)	0.6±0.1	1.0±0.1^∗∗∗	0.7±0.2	0.5±0.1^†††
ALT (IU/L)	34.3±5.6	91.3±29.1^∗∗∗	31.7±8.7	52.1±4.3^†††
AST (IU/L)	128.2±49.6	153.4±45.3	126.0±29.9	128.9±20.1
ALP (IU/L)	144.2±43.7	243.0±73.3^∗∗∗	151.0±23.7	163.1±34.4^†††

Data are presented as mean ± SD. **𝑃<.01, ***𝑃<.001 versus NC group. ^†𝑃<.05, ^††𝑃<.01, and ^†††𝑃<.001 versus HFD group.
FPG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TG: triglyceride; FFA: free fatty acid; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: alkaline phosphatase.